Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
TVTX

TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

7.56USD+0.25 (+3.42%)Delayed as of 24 Jun 2024, 01:55 pm ET

Market Summary

TVTX
USD7.56+0.25
Delayedas of 24 Jun 2024, 01:55 pm
3.42%

TVTX Alerts

  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

TVTX Stock Price

View Fullscreen

TVTX RSI Chart

TVTX Valuation

Market Cap

556.5M

Price/Earnings (Trailing)

-3.45

Price/Sales (Trailing)

3.57

EV/EBITDA

-2.44

Price/Free Cashflow

-1.75

TVTX Price/Sales (Trailing)

TVTX Profitability

EBT Margin

-266.75%

Return on Equity

-217.53%

Return on Assets

-24.28%

Free Cashflow Yield

-57.25%

TVTX Fundamentals

TVTX Revenue

Revenue (TTM)

155.7M

Rev. Growth (Yr)

33.95%

Rev. Growth (Qtr)

-8.18%

TVTX Earnings

Earnings (TTM)

-161.1M

Earnings Growth (Yr)

-57.6%

Earnings Growth (Qtr)

-50.89%

Breaking Down TVTX Revenue

52 Week Range

7.0017.57
(Low)(High)

Last 7 days

2.0%

Last 30 days

11.4%

Last 90 days

-7.2%

Trailing 12 Months

-55.5%

How does TVTX drawdown profile look like?

TVTX Financial Health

Current Ratio

2.78

Debt/Equity

5.1

Debt/Cashflow

-0.84

TVTX Investor Care

Shares Dilution (1Y)

2.04%

Diluted EPS (TTM)

-2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024155.7M000
2023116.9M120.5M129.5M145.2M
2022126.2M120.6M115.1M109.5M
2021198.0M204.1M221.2M131.8M
2020183.5M187.3M194.0M198.3M
2019165.4M168.8M172.4M175.3M
2018159.7M162.3M162.7M164.2M
2017138.2M143.7M150.1M154.9M
2016111.5M120.8M126.7M133.6M
201545.5M63.9M83.5M99.9M
20147.3M14.3M21.2M28.2M
20136.8M4.7M2.5M360.0K
20120009.0M
20110000

Tracking the Latest Insider Buys and Sells of Travere Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 08, 2024
meckler jeffrey a
acquired
-
-
6,500
-
May 08, 2024
coughlin timothy
acquired
-
-
6,500
-
May 08, 2024
squarer ron
acquired
-
-
6,500
-
May 08, 2024
bruhn suzanne louise
acquired
-
-
6,500
-
May 08, 2024
baynes roy d.
acquired
-
-
6,500
-
May 08, 2024
poole sandra
acquired
-
-
6,500
-
May 08, 2024
lyons gary a
acquired
-
-
6,500
-
May 08, 2024
orwin john a
acquired
-
-
6,500
-
May 08, 2024
williams brinkley ruth
acquired
-
-
6,500
-
Apr 11, 2024
cline christopher r.
sold
-363
6.74
-54.00
chief financial officer

1–10 of 50

Which funds bought or sold TVTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-50,000
230,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
sold off
-100
-9,835,060
-
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
68.61
34,967
112,967
0.01%
May 20, 2024
Virtu Financial LLC
sold off
-100
-175,000
-
-%
May 16, 2024
Garner Asset Management Corp
sold off
-100
-9,786
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.99
-131,181
577,348
-%
May 16, 2024
JANE STREET GROUP, LLC
added
54.39
734,414
3,000,790
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-8.26
-298,323
2,119,890
-%
May 16, 2024
COMERICA BANK
reduced
-24.48
-1,965
3,618
-%
May 15, 2024
Point72 Asset Management, L.P.
new
-
6,723,890
6,723,890
0.02%

1–10 of 39

Are Funds Buying or Selling TVTX?

Are funds buying TVTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TVTX
No. of Funds

Unveiling Travere Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 01, 2024
rock springs capital management lp
5.79%
4,411,983
SC 13G
Feb 14, 2024
armistice capital, llc
9.83%
7,384,000
SC 13G/A
Feb 14, 2024
deep track capital, lp
9.99%
7,522,281
SC 13G/A
Feb 14, 2024
macquarie group ltd
6.31%
4,746,144
SC 13G/A
Feb 13, 2024
vanguard group inc
7.34%
5,515,143
SC 13G/A
Feb 12, 2024
janus henderson group plc
0.0%
32,180
SC 13G/A
Feb 09, 2024
morgan stanley
5.5%
4,152,446
SC 13G
Feb 07, 2024
adage capital partners gp, l.l.c.
0.67%
5e+05
SC 13G/A
Jan 25, 2024
state street corp
7.12%
5,352,345
SC 13G/A
Jan 24, 2024
blackrock inc.
10.6%
7,990,020
SC 13G/A

Recent SEC filings of Travere Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 14, 2024
S-8
Employee Benefits Plan
May 13, 2024
8-K
Current Report
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading

Peers (Alternatives to Travere Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Travere Therapeutics, Inc. News

Latest updates
Defense World35 hours ago
Insider Monkey3 months ago

Travere Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-8.2%41,374,00045,059,00037,095,00032,196,00030,888,00029,339,00028,075,00028,634,00023,412,00045,814,50068,217,00054,617,00047,407,00050,983,00051,139,00048,430,00047,769,00046,688,00044,373,00044,707,00039,570,000
Costs and Expenses29.7%180,611,000139,292,000129,680,000136,147,000128,257,000116,041,000110,679,000107,160,00095,393,00046,445,00099,928,00089,932,00094,956,000169,533,00070,574,00071,541,00062,836,00074,855,00078,810,00081,236,00077,798,000
Operating Expenses-----------------62,836,000-78,810,00081,236,00077,798,000
  S&GA Expenses5.9%64,223,00060,671,00067,801,00074,037,00065,950,00051,209,50052,420,00052,979,00046,788,00018,476,00036,065,00034,965,00036,778,00035,738,00031,951,00034,971,00033,139,00027,533,00029,779,00038,970,00032,669,000
  R&D Expenses-----------48,407,00051,807,00047,946,000-32,349,00030,790,00030,249,00036,366,00033,220,00037,934,00033,443,000
EBITDA Margin-3.5%-2.34-2.26-2.53-2.73-2.67-2.74-2.79-2.18-1.77-1.49-0.99-1.01---------
Interest Expenses-2,800,000---2,900,000----5,570,000360,000988,000409,0002,486,5001,123,0001,316,0001,976,000-206,0002,467,0002,589,0002,819,000
Income Taxes180.9%191,00068,00012,00065,00078,00063,000145,00053,00052,00010,50043,00049,000300,000-471,00023,00065,000-18,976,00032,000-523,00069,000401,000
Earnings Before Taxes-53.4%-135,767,000-88,528,000-89,229,000-101,867,000-96,486,000-85,573,000-83,918,000-79,970,000-81,694,000-88,770,000-35,596,000-38,963,000-53,554,000-122,093,000-22,526,000-26,003,000-18,168,000-30,227,000-37,013,000-38,632,000-40,576,000
EBT Margin-3.0%-2.67-2.59-2.88-3.05-2.96-3.03-2.91-2.37-1.94-1.65-1.13-1.16---------
Net Income-50.9%-136,061,000-90,173,000150,735,000-85,630,000-86,331,000-65,823,000-69,656,000-67,032,000-75,971,000-51,573,000-35,639,000-39,012,000-53,867,000-121,622,000-22,549,000-26,068,000808,000-30,259,000-36,490,000-38,701,000-40,977,000
Net Income Margin-34.9%-1.03-0.77-0.67-2.55-2.47-2.54-2.30-1.91-1.60-1.37-1.13-1.16---------
Free Cashflow-68.8%-119,005,000-70,498,000-59,764,000-69,927,000-81,747,000-54,670,000-39,538,000-36,823,000-55,451,000-27,031,00031,714,0006,393,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-15.9%664789833736808673726779828777775747764607692679573605614648668
  Current Assets-22.0%481617686542605486535587631583579550565410498506407429440457476
    Cash Equivalents-25.7%43.0058.0014471.0016162.0015118025716615083.0014885.0020023767.0062.0065.0076.0070.00
  Inventory349.6%42.009.0021.0019.007.005.007.008.007.007.007.007.007.008.007.006.007.006.005.005.006.00
  Net PPE-7.2%7.007.008.009.009.009.0010.0010.0011.0011.0012.0012.0012.009.006.003.003.003.003.003.003.00
  Goodwill0%1.001.00--------1.001.001.001.001.001.001.001.001.001.001.00
Liabilities0.2%589588553620619630626623620475468414401396391360347384368370382
  Current Liabilities-2.6%17317813913613114213112411912411397.0085.0093.0075.0070.0068.0095.0088.0091.00104
  Long Term Debt0.1%378377377376376376375375374227224221218215213210207205202200197
    LT Debt, Current---------------------23.00
    LT Debt, Non Current0.1%378377377376376376375375374227224221218215213210207205202200197
Shareholder's Equity-63.1%74.0020128011618943.00101157208302307332363211301319226221246277286
  Retained Earnings-12.1%-1,261-1,125-1,035-1,186-1,100-1,014-948-878-811-765-714-678-639-585-464-441-415-416-386-349-310
  Additional Paid-In Capital0.7%1,3381,3281,3191,3071,2921,0601,0491,0371,0221,0691,0221,0121,003798765759643637631626597
Shares Outstanding1.0%76.0075.0075.0075.0068.0064.0064.0063.0063.0060.0059.0058.00---------
Float----1,145---1,539---879---1,031---853-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-68.9%-119,005-70,473-59,134-69,297-81,117-54,640-39,525-36,806-55,320-26,87732,0636,496-26,474-13,8706,735-6,453-29,155-4,492-14,121-19,109-20,492
  Share Based Compensation19.8%9,7588,14410,73411,89713,4719,2978,02312,6378,1867,3766,9867,2967,9087,0015,1395,5645,9105,0044,1545,6766,271
Cashflow From Investing718.9%104,898-16,950133,318-23,553-37,039-36,70110,079-39,09633,1657,37032,520-71,807-105,706-125,511-43,16967,80239,5511,5804,46525,230-11,412
Cashflow From Financing-523.4%-525124-6342,266216,9965512,278831113,91333,2132,414303195,75325,039-348108,795-5,77395.00-738-324-1,110
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TVTX Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 41,374$ 30,888
Operating expenses:  
Cost of goods sold1,5044,145
Research and development49,42058,162
Selling, general and administrative64,22365,950
In-process research and development65,2050
Restructuring2590
Total operating expenses180,611128,257
Operating loss(139,237)(97,369)
Other income (expenses), net:  
Interest income6,0323,646
Interest expense(2,800)(2,850)
Other income, net23887
Total other income, net3,470883
Loss from continuing operations before income tax provision(135,767)(96,486)
Income tax provision on continuing operations(191)(78)
Loss from continuing operations, net of tax(135,958)(96,564)
(Loss) income from discontinued operations, net of tax(103)10,233
Net loss$ (136,061)$ (86,331)
Basic and diluted:  
Net loss from continuing operations, basic (in dollars per share)$ (1.76)$ (1.42)
Net loss from continuing operations, diluted (in dollars per share)(1.76)(1.42)
Net income from discontinued operations, basic (in dollars per share)00.15
Net income from discontinued operations, diluted (in dollars per share)00.15
Net loss per common share, basic (in dollars per share)(1.76)(1.27)
Net loss per common share, diluted (in dollars per share)$ (1.76)$ (1.27)
Weighted average common shares outstanding, basic (in shares)77,136,49368,174,099
Weighted average common shares outstanding, diluted (in shares)77,136,49368,174,099
Comprehensive loss:  
Net loss$ (136,061)$ (86,331)
Foreign currency translation gain (loss)629(566)
Unrealized (loss) gain on marketable debt securities(1,065)1,297
Comprehensive loss(136,497)(85,600)
Net product sales  
Total revenue39,98424,178
Operating expenses:  
Cost of goods sold1,5041,108
License and collaboration revenue  
Total revenue1,3906,710
Operating expenses:  
Cost of goods sold$ 0$ 3,037

TVTX Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 43,251$ 58,176
Marketable debt securities, at fair value397,793508,675
Accounts receivable, net22,73121,179
Inventory4,5329,410
Prepaid expenses and other current assets12,76919,335
Total current assets481,076616,775
Long-term inventory37,77431,494
Property and equipment, net6,9437,479
Operating lease right of use assets17,27118,061
Intangible assets, net101,182104,443
Other assets19,30110,661
Total assets663,547788,913
Current liabilities:  
Accounts payable16,72541,675
Accrued expenses139,580118,991
Deferred revenue, current portion6,4607,096
Operating lease liabilities, current portion5,0364,909
Other current liabilities5,4285,237
Total current liabilities173,229177,908
Convertible debt377,693377,263
Deferred revenue, less current portion8881,835
Operating lease liabilities, less current portion21,28722,612
Other non-current liabilities16,3798,485
Total liabilities589,476588,103
Commitments and Contingencies (See Note 13)
Stockholders' Equity:  
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock $0.0001 par value; 200,000,000 shares authorized; 76,108,829, and 75,367,117 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively87
Additional paid-in capital1,337,6381,327,881
Accumulated deficit(1,261,683)(1,125,622)
Accumulated other comprehensive loss(1,892)(1,456)
Total stockholders' equity74,071200,810
Total liabilities and stockholders' equity$ 663,547$ 788,913
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
 CEO
 WEBSITEtravere.com
 INDUSTRYBiotechnology
 EMPLOYEES462

Travere Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Travere Therapeutics, Inc.? What does TVTX stand for in stocks?

TVTX is the stock ticker symbol of Travere Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Travere Therapeutics, Inc. (TVTX)?

As of Fri Jun 21 2024, market cap of Travere Therapeutics, Inc. is 556.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers. The fair value of Travere Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Travere Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Travere Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TVTX is over valued or under valued. Whether Travere Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Travere Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TVTX.

What is Travere Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, TVTX's PE ratio (Price to Earnings) is -3.45 and Price to Sales (PS) ratio is 3.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TVTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Travere Therapeutics, Inc.'s stock?

In the past 10 years, Travere Therapeutics, Inc. has provided -0.044 (multiply by 100 for percentage) rate of return.